Histone deacetylase inhibitor romidepsin has differential activity in core binding factor acute myeloid leukemia.
Odenike OM, Alkan S, Sher D, Godwin JE, Huo D, Brandt SJ, Green M, Xie J, Zhang Y, Vesole DH, Stiff P, Wright J, Larson RA, Stock W.
Odenike OM, et al. Among authors: godwin je.
Clin Cancer Res. 2008 Nov 1;14(21):7095-101. doi: 10.1158/1078-0432.CCR-08-1007.
Clin Cancer Res. 2008.
PMID: 18981008
Free PMC article.
Clinical Trial.